M&A and Life Sciences |
Publish date:
By 2012 drugs representing over $74 billion in sales will lose patent protection and therefore face the possibility of competition from generic manufacturers. This “patent cliff,” combined with the current uncertainty surrounding healthcare reform, is causing pharmaceutical companies to revaluate their business development strategies. Learn how the issues facing life sciences companies differ significantly from other sectors. Below we have provided resources and materials designed to help you in your efforts to minimize your risks and maximize your returns.
Thoughtware
Acquisitions Versus Product Development: An Emerging Trend in Life Sciences
This piece, based on insights from Deloitte Recap, helps pharmaceutical and biotech executives understand factors driving the industry to later-stage deals.
A conversation With Phil Pfrang
2008 Directorship Healthcare Life Sciences interview with Phil Pfrang National Healthcare and Life Sciences Industry Leader.
Upcoming Events
Deloitte & The BioExec Institute, December 8 & 9, 2009